Edaravone Patent Expiration
Edaravone is Used for the treatment of amyotrophic lateral sclerosis (ALS). It was first introduced by Mitsubishi Tanabe Pharma Corp
Edaravone Patents
Given below is the list of patents protecting Edaravone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Radicava Ors | US12194025 | Pharmaceutical composition for oral administration of edaravone and method of administering same | Nov 12, 2041 | Mitsubishi Tanabe |
| Radicava Ors | US12310946 | Pharmaceutical composition for oral administration of edaravone and method of administering same | Nov 12, 2041 | Mitsubishi Tanabe |
| Radicava Ors | US10987341 | Edaravone suspension for oral administration | Nov 01, 2039 | Mitsubishi Tanabe |
| Radicava Ors | US11241416 | Edaravone suspension for oral administration | Nov 01, 2039 | Mitsubishi Tanabe |
| Radicava Ors | US11478450 | Edaravone suspension for oral administration | Nov 01, 2039 | Mitsubishi Tanabe |
| Radicava Ors | US11826352 | Edaravone suspension for oral administration | Nov 01, 2039 | Mitsubishi Tanabe |
| Radicava Ors | US11957660 | Edaravone suspension for oral administration | Nov 01, 2039 | Mitsubishi Tanabe |
| Radicava Ors | US12285409 | Edaravone suspension for oral administration | Nov 01, 2039 | Mitsubishi Tanabe |
| Radicava | US6933310 | Therapeutic agent for amyotrophic lateral sclerosis (ALS) |
Nov 13, 2020
(Expired) | Mitsubishi Tanabe |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Edaravone's patents.
Latest Legal Activities on Edaravone's Patents
Given below is the list recent legal activities going on the following patents of Edaravone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical
| 16 Apr, 2024 | US11957660 |
| Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
| Email Notification Critical
| 16 Apr, 2024 | US11957660 |
| Mail Patent eGrant Notification | 16 Apr, 2024 | US11957660 |
| Recordation of Patent eGrant | 16 Apr, 2024 | US11957660 |
| Patent Issue Date Used in PTA Calculation Critical
| 16 Apr, 2024 | US11957660 |
| Email Notification Critical
| 28 Mar, 2024 | US11957660 |
| Issue Notification Mailed Critical
| 27 Mar, 2024 | US11957660 |
| Dispatch to FDC | 21 Mar, 2024 | US11957660 |
| Application Is Considered Ready for Issue Critical
| 21 Mar, 2024 | US11957660 |
Edaravone's Family Patents
